Clinical Research Committee awards

Update to clinical schemes

Please note that all clinical funding schemes have been replaced with a single, modular scheme supporting clinical trials, experimental medicine and sample collection. Awards from 2025 onward will reflect this change.

Biomarker Project Awards

November 2024

Evaluation and refinement of a multigene prognostic signature and digital histology AI features for the prediction of metastasis in cutaneous squamous cell carcinoma

Dr Jun Wang

Queen Mary University of London

Pro-tumourigenic inflammation as a predictor of relapse post-surgery in early-stage non-small cell lung cancer

Dr Santiago Zelenay

Cancer Research UK Manchester Institute

Professor Caroline Dive

Cancer Research UK Manchester Institute

Prospective Sample Collection Awards

November 2024

Augmenting radiotherapy in rectal cancer to minimise invasive surgery (ARTEMIS) sample collection

Professor Simon Gollins

University of Leeds

Professor David Sebag-Montefiore

University of Leeds

Dr Mark Saunders

University of Leeds

Sample collection in early preoperative intervention studies in glioblastoma: POBIG and PORTRAIT

Dr Claire O’Leary

University of Manchester

Clinical Trial Awards

November 2024

CONNECT2007: Phase I/II study of lutathera in patients with recurrent and/or progressive high-grade central nervous system tumours and meningiomas that demonstrate uptake on DOTATATE PET

Dr Jenny Gains

University College London

Professor Darren Hargrave

University College London

A phase II/III trial evaluating use of circulating serum miRNA as part of active surveillance for patients with stage I seminoma and dysgerminoma (OTIS-S)

Professor Robert Huddart

The Institute of Cancer Research

Dr Alison Reid

The Institute of Cancer Research

Dr Fay Cafferty

The Institute of Cancer Research

Experimental Medicine Awards

November 2024

BIOINFORM: Biologically informed treatment decisions in acute leukaemia

Professor Anthony Moorman

Newcastle University

Clinical Trial Award Endorsement

November 2024

RAdICAL - risk-adapted immunochemotherapy to cure aggressive lymphoma

Professor Christopher Fox

University of Nottingham

SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVage weekly dose-dense regimen in patients with poor prognostic OVARian cancers based on the tumour primary chemosensitivity and incomplete debulking surgery

Dr Andrew Clamp

University College London